Skip to main content
SpringerLink
Log in

Aspirin and Ticlopidine After Routine Coronary Stenting: The Gold Standard as of 1999

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  1. Popma JJ, Coller BS, Ohman EM, et al. Antithrombotic therapy in patients undergoing coronary angioplasty. Chest 1995;108:486S–501S.

    Google Scholar 

  2. Pepine CJ, Holmes DRJ. Coronary artery stents. American College of Cardiology. J Am Coll, Cardiol 1996;28:782–794.

    Google Scholar 

  3. Hall P, Nakamura S, Maiello L, et al. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasoundguided stent implantation. Circulation 1996;93:215–222.

    Google Scholar 

  4. Schatz RA. The evolution of antithrombotic therapy in coronary stenting. Am Heart J 1997;134:S78–S80.

    Google Scholar 

  5. Pomma JJ, Weitz J, Bittle JA, et al. Antithrombotic therapy in patients undergoing coronary angioplasty. Chest 1998; 114:7285–7415.

    Google Scholar 

  6. Schomig A, Neumann FJ, Walter H, et al. Coronary stent placement in patients with acute myocardial infarction: Comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy. J Am Coll Cardiol 1997;29:28–34.

    Google Scholar 

  7. McCullough PA, Wolyn R, Rocher LL, et al. Acute renal failure after coronary intervention: Incidence, risk factors, and relationship to mortality. Am J Med 1997;103:368–375.

    Google Scholar 

  8. Cutlip DE, Kalon KL, Baim DS, et al. Predictors and clinical outcomes of stent thrombosis—a pooled analysis of 5000 patients from multicenter randomized trials (abstr). Circulation 1998;98:I 495.

    Google Scholar 

  9. Kong DF, Califf RM. Post-procedure heparin: Boon or burden? Am Heart J 1998;136:183–185.

    Google Scholar 

  10. Albiero R, Hall P, Itoh A, et al. Results of a consecutive series of patients receiving only antiplatelet therapy after optimized stent implantation. Comparison of aspirin alone versus combined ticlopidine and aspirin therapy. Circulation 1997;95:1145–1156.

    Google Scholar 

  11. Stalnikowicz-Darvasi R. Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events. A critical analysis. Clin Gastroenterol 1995;21:13–16.

    Google Scholar 

  12. Roche Laboratories. Ticlid (ticlopidine hydrochloride) [product information]. Nutley, NJ, 1998.

  13. Schuhlen H, Hadamitzky M, Walter H, et al. Major benefit from antiplatelet therapy for patients at high risk for adverse cardiac events after coronary Palmaz-Schatz stent placement: Analysis of a prospective risk stratification protocol in the Intracoronary Stenting and Antithrombotic Regimen (ISAR) trial. Circulation 1997;95: 2015–2021.

    Google Scholar 

  14. Steinhubl SR, Lauer MS, Mukherjee DP, et al. The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions. J Am Coll Cardiol 1998;32:1366–1370.

    Google Scholar 

  15. Szto G, Linnemeier T, Lewis S, et al. Safety of 10 days of ticlopidine after coronary stenting—a randomized comparison with 30 days: Strategic Alternatives with Ticlopidine in Stenting Study (SALTS) (abstr). J Am Coll Cardiol. 1998; 31:352.

    Google Scholar 

  16. Schuhlen H, Kastrati A, Hausleiter J, et al. Two or fourweek ticlopidine therapy after coronary stent placement? (abstr) Circulation 1998;98:I572.

    Google Scholar 

  17. Wysowksi DK, Bacsanyi J. Blood dyscrasias and hematologic reactions in ticlopidine users. JAMA 1996;276:952.

    Google Scholar 

  18. Barnett H, Eliasziw M, Meldrum H. Prevention of ischemic stroke. N Engl J Med 1995;333:460.

    Google Scholar 

  19. Janzon L. The STIMS trial: The ticlopidine experience and its clinical applications. Swedish Ticlopidine Multicenter Study. Vasc Med 1996;1:141–143.

    Google Scholar 

  20. Bennett C, Weinberg P, Rozenberg-Ben-Dror K, et al. Thrombotic thrombocytopenic purpura associated with ticlopidine. Ann Intern Med 1998;128:541–544.

    Google Scholar 

  21. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996;348:1329–1339.

    Google Scholar 

  22. Lablanche JM, McFadden EP, Bonnet JL, et al. Combined antiplatelet therapy with ticlopidine and aspirin. A simplified approach to intracoronary stent management. Eur Heart J 1996;17:1373–1380.

    Google Scholar 

  23. Goods CM, Al-Shaibi KF, Liu MW, et al. Comparison of aspirin alone versus aspirin plus ticlopidine after coronary artery stenting. Am J Cardiol 1996;78:1042–1044.

    Google Scholar 

  24. Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084–1089.

    Google Scholar 

  25. Leon MB, Baim DS, Gordon P, et al. Clinical and angiographic results from the Stent Anticoagulation Regimen Study (STARS) (abstr). Circulation 1997;96:I685.

    Google Scholar 

  26. Monassier JP, Hamon M, Elias J, et al. Early versus late coronary stenting following acute myocardial infarction: Results of the STENTIM I Study (French Registry of Stenting in Acute Myocardial Infarction). Cathet Cardiovasc Diagn 1997;42:243–248.

    Google Scholar 

  27. Torok TJ, Holman RC, Chorba TL. Increasing mortality from thrombotic thrombocytopenic purpura in the United States—analysis of national mortality data, 1968–1991. Am J Hematol 1995;50:84–90.

    Google Scholar 

  28. Schuhlen H, Kastrati A, Dirschinger J, et al. Intracoronary stenting and risk for major adverse cardiac events during the first month. Circulation 1998;98:104–111.

    Google Scholar 

  29. Thacker, KM. New prescriptions for ticlid by year (1994–1997). Nutley, NJ Roche Laboratories, 1998.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiovascular Division, Henry Ford Hospital Henry Ford Health System Center for Clonical Effectiveness, Detroit, Michigan, USA

    Peter A. McCullough & Keisha R. Marks

Authors
  1. Peter A. McCullough
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Keisha R. Marks
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

McCullough, P.A., Marks, K.R. Aspirin and Ticlopidine After Routine Coronary Stenting: The Gold Standard as of 1999. J Thromb Thrombolysis 7, 233–239 (1999). https://doi.org/10.1023/A:1008922925054

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1008922925054

Keywords

Search

Navigation